Guardian Pharmacy Services, Inc.

NYSE:GRDN

Medical - Distribution

Healthcare
$48.84 +0.39%

+$0.17 today

Market cap
$3.09B
Beta
0.08
P/E (TTM)
52.0
EPS (TTM)
$0.84
52W Low $19.30High $44.00

Volume 0.45M

Average 0.48M

GRDN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Guardian Pharmacy Services, Inc.NYSE: GRDN

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development remains negative

Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How GRDN compares with its peers on the latest reported figures

  • GRDN's LTM Jun 2026 research & development of $0 is the 9th highest of the 11 companies compared; the peer median is $112.58M.
  • Research & development amounts to 0.0% of revenue for GRDN, versus a peer median of 22.7%.
GRDN Competitors Peer median
Research & Development for GRDN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TXG10x Genomics, Inc.LTM Sep 2026$222.54M -10.9%-3.5%36.0%
QDELQuidelOrtho CorporationLTM Mar 2026$177.9M -16.4%-0.3%6.7%
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$165.37M +14.7%+41.0%—
NUVBNuvation Bio Inc.LTM Jun 2026$128.85M +18.2%+9.4%75.8%
JANXJanux Therapeutics, Inc.LTM Mar 2026$127.65M +60.8%+33.1%590.6%
MESOMesoblast LimitedLTM Jun 2026$97.51M +180.1%+53.3%81.1%
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026$73.13M +11.5%+35.0%22.7%
TWSTTwist Bioscience CorporationLTM Sep 2026$71.84M -10.5%-12.4%15.6%
GRDNGuardian Pharmacy Services, Inc.LTM Jun 2026$0 ——0.0%
NHCNational HealthCare CorporationLTM Sep 2026$0 ——0.0%
MDPediatrix Medical Group, Inc.LTM Sep 2026$0 ——0.0%
Peer median (excluding GRDN) $112.58M+13.1%+21.2%22.7%

Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue792.07M908.91M1.05B1.23B1.45B
Cost of Revenue630.81M723.04M837.88M984.04M1.17B
Gross Profit161.27M185.87M208.31M244.37M282.04M
Gross Margin20.4%20.4%19.9%19.9%19.5%
Research & Development00000
Selling, General & Admin131.12M133.88M167.36M307.29M193.13M
Operating Expenses131.12M133.88M167.36M307.29M193.13M
Depreciation & Amortization16.53M16.56M18.23M19.77M22.34M
EBITDA46.49M68.15M58.81M(43.43M)96.42M
EBITDA Margin5.9%7.5%5.6%-3.5%6.7%
Operating Income30.15M51.99M40.95M(62.92M)88.91M
Operating Margin3.8%5.7%3.9%-5.1%6.1%
Interest Income00000
Interest Expense1.64M1.93M2.86M3.28M665K
Other Income / Expenses(1.82M)(2.33M)(3.23M)(3.56M)(15.49M)
Income Before Tax28.33M49.66M37.72M(66.48M)73.42M
Pre-Tax Margin3.6%5.5%3.6%-5.4%5.1%
Income Tax Expense0004.56M24.47M
Net Income16.31M35.42M23.9M(87.29M)49.22M
Net Margin2.1%3.9%2.3%-7.1%3.4%
EPS (Basic)0.270.580.39(1.77)0.79
EPS (Diluted)0.270.580.39(1.77)0.78
Weighted Avg Shares60.84M60.84M60.84M62.01M62.39M
Weighted Avg Shares (Diluted)60.84M60.84M60.84M62.01M63.3M

Guardian Pharmacy Services, Inc.

NYSE:GRDN

Intrinsic Alpha fair value

Locked

Current Price

$48.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.